Literature DB >> 24351446

First symptoms and their age of onset in macular telangiectasia type 2.

Tjebo F C Heeren1, Frank G Holz, Peter Charbel Issa.   

Abstract

PURPOSE: To investigate the first symptoms and their age of onset in a large cohort of patients with macular telangiectasia type 2.
METHODS: Patients with the characteristic findings of macular telangiectasia type 2 were interviewed. Data collection also included a chart review to determine the delay of the correct diagnosis and visual function 10 years after the onset of first symptoms.
RESULTS: Of 91 patients, 72 (79%) reported impaired reading ability as their first symptom, followed by metamorphopsia in 12%. The age of onset was most frequent (76%) in the sixth or seventh decade of life (50-69 years), and 58% of the patients were symptomatic before the age of 60 years. The median delay between first symptoms and the diagnosis of macular telangiectasia type 2 before the year 2005 was 7 years and has decreased to 1 year thereafter. Ten years after the onset of first symptoms, distance visual acuity of the better eye was ≥20/25 in 35% and ≤20/50 in 17%.
CONCLUSION: Impaired reading ability was the most common initial visual disturbance of patients with macular telangiectasia type 2, starting generally between the age of 50 and 70 years. Knowledge of the presenting symptoms of macular telangiectasia type 2 together with recently identified characteristic morphologic alterations on retinal imaging will likely lead to earlier accurate diagnosis of this disease entity.

Entities:  

Mesh:

Year:  2014        PMID: 24351446     DOI: 10.1097/IAE.0000000000000082

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  11 in total

1.  FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.

Authors:  Zhongjie Fu; Yan Gong; Raffael Liegl; Zhongxiao Wang; Chi-Hsiu Liu; Steven S Meng; Samuel B Burnim; Nicholas J Saba; Thomas W Fredrick; Peyton C Morss; Ann Hellstrom; Saswata Talukdar; Lois E H Smith
Journal:  Cell Rep       Date:  2017-02-14       Impact factor: 9.423

2.  [Morphological characteristics in macular telangiectasia type 2].

Authors:  P Charbel Issa; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; F G Holz
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

3.  Demographic features of idiopathic macular telangiectasia in Korean patients.

Authors:  Sung Hyun Kim; Jaeryung Oh; Soh-Eun Ahn; Choul Yong Park; Jong-Hyun Oh
Journal:  Korean J Ophthalmol       Date:  2015-05-20

4.  Macular telangiectasia type 2 (MacTel) in a 34-year-old patient.

Authors:  Heleen Nicolai; Mieke Wirix; Leigh Spielberg; Anita Leys
Journal:  BMJ Case Rep       Date:  2014-09-23

5.  [Functional characteristics of macular telangiectasia type 2].

Authors:  T F C Heeren; E Krüger; F G Holz; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

6.  CONCURRENT IDIOPATHIC MACULAR TELANGIECTASIA TYPE 2 AND CENTRAL SEROUS CHORIORETINOPATHY.

Authors:  Alexandre Matet; Suzanne Yzer; Emily Y Chew; Alejandra Daruich; Francine Behar-Cohen; Richard F Spaide
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

7.  Macular Abnormalities Associated With 5α-Reductase Inhibitor.

Authors:  Yong Kyun Shin; Geun Woo Lee; Se Woong Kang; Sang Jin Kim; A Young Kim
Journal:  JAMA Ophthalmol       Date:  2020-07-01       Impact factor: 7.389

8.  Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2.

Authors:  Alice Behrens; Ahmed Sallam; John Pemberton; Sami Uwaydat
Journal:  Case Rep Ophthalmol       Date:  2018-01-17

9.  Systemic lipid dysregulation is a risk factor for macular neurodegenerative disease.

Authors:  Roberto Bonelli; Sasha M Woods; Brendan R E Ansell; Tjebo F C Heeren; Catherine A Egan; Kamron N Khan; Robyn Guymer; Jennifer Trombley; Martin Friedlander; Melanie Bahlo; Marcus Fruttiger
Journal:  Sci Rep       Date:  2020-07-22       Impact factor: 4.379

10.  Longitudinal Assessment of Remnant Foveal Cone Structure in a Case Series of Early Macular Telangiectasia Type 2.

Authors:  Katie M Litts; Mali Okada; Tjebo F C Heeren; Angelos Kalitzeos; Vincent Rocco; Rebecca R Mastey; Navjit Singh; Thomas Kane; Melissa Kasilian; Marcus Fruttiger; Michel Michaelides; Joseph Carroll; Catherine Egan
Journal:  Transl Vis Sci Technol       Date:  2020-03-30       Impact factor: 3.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.